Articles tagged with: IPH 2101
News»
Yesterday was the second day of the American Society of Hematology’s (ASH) annual meeting, which is being held in New Orleans.
As on Saturday, myeloma-related presentations were once again made during several sessions throughout the day.
Experts who missed the education session on Saturday had the opportunity to attend the session again early Sunday morning.
One myeloma study was presented during the plenary session in the early afternoon. The six presentations in this session covered all blood cancers and are considered particularly important studies.
The myeloma study included in this session was …
News»
At this year’s American Society of Hematology (ASH) meeting, which will be held in early December, more than 100 oral presentations and about 400 poster presentations will summarize research focused on multiple myeloma.
Abstracts for these presentations are now available.
During the next several weeks, The Beacon will publish a series of articles previewing the myeloma-related studies from the ASH meeting that are of particular interest.
Each of the articles will cover abstracts related to a specific topic, such as new treatments under development, current treatments, stem cell transplantation, prognostic factors, and …
News»
Monday was the third and next-to-last day of the 2012 American Society of Hematology (ASH) annual meeting.
It also was the busiest day of the meeting in regard to myeloma-related research.
The day ended with a poster session in the evening that featured over 1000 posters displayed throughout a large conference hall. More than a hundred of the posters reported on the results of myeloma-related research.
Compared to the research summarized during oral presentations, the findings in poster summaries generally are in earlier stages of development. They may involve laboratory research, clinical …
NewsFlash »
NCI Initiates Study Of Novel Imaging Techniques To Identify Precursor Stages Of Myeloma – The National Cancer Institute (NCI) is recruiting patients for a study investigating the use of sensitive imaging technologies to identify progression of myeloma precursor diseases. There are currently no diagnostic tests available to determine whether an individual with monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma will develop multiple myeloma. New and improved imaging techniques may help physicians better detect the progression of these precursor diseases. This trial is recruiting participants with MGUS, smoldering myeloma, or myeloma. For more information, see the clinical trial description. To participate in the trial, please contact the research nurse, Mary Ann Yancey, at (301) 435-9227 or .
Phase 2 Trials Of IPH 2101 Are Recruiting Myeloma And Smoldering Myeloma Patients – Several Phase 2 clinical trials are now recruiting multiple myeloma and smoldering multiple myeloma patients to receive the experimental agent IPH 2101 (anti-KIR). IPH 2101 is an antibody drug being developed by Innate Pharma. It helps activate cells of the immune system to destroy cancer cells. IPH 2101 is being studied in patients with smoldering myeloma to see if it delays and/or prevents progression to multiple myeloma (trial description). It is also being studied in multiple myeloma patients in stable partial response after a first line therapy (trial description) and in combination with Revlimid (lenalidomide) in myeloma patients experiencing their first relapse (trial description). To participate in the smoldering myeloma trial at the National Institutes of Health, please contact the research nurse, Mary Ann Yancey, at (301) 435-9227 or .
Phase 3 Double Transplant Trial Is Currently Recruiting Myeloma Patients – Myeloma patients are now being recruited by the Hackensack University Medical Center in New Jersey to participate in a Phase 3 trial of tandem stem cell transplants with melphalan (Alkeran) followed by melphalan and Velcade (bortezomib). The purpose of this trial is to determine if the addition of Velcade to the second transplant will increase remission times. For more information, please see the clinical trial description.
NewsFlash »
Dr. Ken Anderson Elected Officer To American Society Of Hematology – Dr. Ken Anderson is one of five newly elected officers to the American Society of Hematology’s (ASH) Executive Committee. Dr. Anderson is a renowned hematologist specializing in the treatment of multiple myeloma. He will begin serving his four-year term in January 2010. For more information, please see the ASH press release.
Revlimid Covered By Australian Government – Revlimid (lenalidomide) is now listed for the treatment of myeloma on the Pharmaceutical Benefits Scheme, a list of drugs subsidized by the Australian government. Revlimid will be subsidized for the next four years at a cost of A$104 million (US$94 million). For more information, please visit the Investor Village Web site.
Potential New Myeloma Treatment Starts Phase 1 Trial Extension For AML – Innate Pharma received approval from the French Regulatory authorities to begin an extension of the Phase 1 trial with IPH 2101 in patients with acute myeloid leukemia (AML). The company recently also started Phase 2 clinical trials with IPH 2101 for multiple myeloma. For more information, please see the Innate Pharma press release (pdf).
MMRF Race For Research – On November 15, the Multiple Myeloma Research Foundation (MMRF) is sponsoring a 5K walk/run. It will be held in Alexandria, VA and will start at 7:30 a.m. The MMRF is looking for participants and sponsors. For more information, please visit the MMRF Web site.
For a more detailed listing of myeloma related events, please check the Myeloma Beacon Events Calendar.